ArticleCureus2025
When 25% Feels Like 100%: Confronting Recurrent Cystic Fibrosis Risk Across Consecutive Pregnancies.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) is the most common autosomal recessive lethal disorder worldwide caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, which represents conditions with variable expressivity and penetrance. CF is not uncommon in India, but with a more genetically heterogeneous mutation spectrum. We present a case where a couple came for preconception counselling after they lost their baby at seven months of age because of CF. Initial targeted exome sequencing of the baby suggested a homozygous pathogenic variant of F508del. The father was a carrier of the F508 variant, while the mother tested negative for this variant. Because of this discrepancy, subsequent testing, multiple ligation-dependent probe amplification (MLPA) was performed, which revealed the mother carried a heterozygous multi-exon deletion (exons 4-11). Re-analysis of preserved tissue of the baby using MLPA diagnosed compound heterozygosity for F508del and the exon 4-11 deletion. This case underscores the importance of combining sequence variant detection with copy number variation (CNV) analysis in CFTR testing to avoid misinterpretation of zygosity. None of the parents had any stigmata of CF-related disease, including congenital bilateral absence of the vas deferens (CBAVD). After discussion, the couple decided on preimplantation genetic testing for monogenic conditions (PGT-M), which yielded a single embryo harboring a compound heterozygous mutation (F508del and exons 4-11). Subsequently, the mother conceived naturally, but prenatal diagnosis by chorionic villus sampling (CVS) found the presence of the same compound heterozygous mutations in the fetus, for which the pregnancy was terminated. Fortunately, in the subsequent spontaneous conception, CVS revealed that the fetus was only heterozygous for exons 4-11, establishing its carrier status. Pregnancy eventually ended in the live birth of the baby, who is now doing well at 20 months of age. Parents, in this case, had a long journey, where the risk of 25% in every pregnancy seemed to be difficult for them to carry on because it recurred three consecutive times in the fetus/embryo(s). This illustrates how statistical probabilities, though clinically accurate, can feel meaningless to those enduring repeated loss, and underscores the profound psychological toll of autosomal recessive disorders. Psychological support, genetic counselling, and ensuring informed decision-making are crucial for parents coping with the psychological impact of having a child with a rare disease. In this case, it is the perseverance of the couple that finally led to a successful outcome. Complexity of genetic analysis and counselling, recurrence three consecutive times, absence of CBAVD in the man despite carrying the CFTR mutation, and finally a successful outcome prompted us to report this case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.